NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Newest GO™ Peptides - Exendins - Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else
AnaSpec Introduces Newest GO™ Peptides - Exendins

 

NewswireTODAY - /newswire/ - San Jose, CA, United States, 2009/02/27 - Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

AnaSpec has added a wide selection of Exendin peptides to it’s GO™ Peptides line of on-demand peptides. Along with a host of popular Exendin peptides, AnaSpec’s GO™ Peptides line includes Fluorescein-Trp25-Exendin-4 (FLEX) and [Cys(HiLyteFluor 647 C2 maleimide)]-Exendin-4 - two exendin peptides that are not immediately available anywhere else.

Fluorescein-Trp25-Exendin-4 (FLEX) is Exendin-4 with a fluorescein covalently attached to Trp at position 25. Useful for binding and characterization studies of the human GLP-1 receptor, FLEX is equipotent to GLP-1 (7-36)-amide and Exendin-4 as an inhibitor of [125I]-GLP-1 binding to the human GLP-1 receptor stably expressed in CHO cells.1 [Cys(HiLyte Fluor™ 647 C2 maleimide)]-Exendin -4 is Exendin-4 with an additional Cys added to the N-terminus. AnaSpec’s patented HiLyte Fluor 647 (Ex/Em=650 nm/675 nm) is attached to the Cys thiol moiety.

Exendin-3 and Exendin-4 are 39-amino acid peptides from exocrine glands that share about 50% sequence identity to Glucagon-Like-Peptide-1 (GLP-1) and are potent GLP-1R agonists. 2,3 Exendin-3 stimulates increases in cellular cAMP and amylase release from dispersed guinea pig pancreatic acini.4 Exendin-4 was originally isolated from the saliva of the lizard Heloderma suspectum. It is an insulinotropic agent which improves glucose tolerance in humans and animals with diabetes. It increases insulin sensitivity via a PI-3-kinase-dependent mechanism. In the human fetal pancreas, the proliferation and differentiation of endocrine precursor cells into insulin-producing ß-cells can be positively regulated by Exendin-4.5 Exendin-4 is an agonist and Exendin (9-39) is an antagonist of the action of GLP-I (7-36) amide on arterial blood pressure and heart rate.6

About AnaSpec

AnaSpec (anaspec.com) is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

References:
1. Chicchi GG. et al. Peptides 18, 319 (1997).
2. Goke, R. et al. J. Biol. Chem. 268, 19650 (1993).
3. Thorens, B. et al. Diabetes 42, 1678 (1993).
4. Eng, J. J. Biol. Chem. 265, 20259 (1990).
5. Movassat, J. et al. J. Clin. Endo. Metab. 87, 4775 (2002).
6. Barragan, JM. Regul. Peptides 67, 63 (1994).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Newest GO™ Peptides - Exendins

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study
Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)